Of the 298 patients from TCGA we analyzed in this study, somatic mutation data was available for 242. For the 242 patients, Kaplan-Meier survival analysis showed that VHL, PBRM1, and BAP1 gene mutations did not correlate significantly with patients' overall survival (all P>0.05; figure 2, left panel) . The five-CpG-based classifier successfully categorized patients into high-risk and low-risk groups with significant differences of clinical outcome in subsets of VHL wild type (P=0.013), VHL mutation (P=0.001), PBRM1 wild type (P=0.0002), PBRM1 mutation (P=0.031), and BAP1 wild type (P=0.0001). In BAP1 mutation subset, although not significant, there is still a trend to different outcomes between high-risk and low-risk groups (P=0.143). The small sample size of 19 patients might explain the negative results in the BAP1 mutation subset. P values were calculated using the logrank test.
Supplementary
: Clinical characteristics and gene mutation status (VHL, BAP1, and PBRM1) for 46 ccRCC patients from the discovery set.
ID
Sex Site pT pN M Clinical stage VHL mutation* BAP1 mutation* PBRM1 mutation *  2014ccRCC01  male  left  T1  N0  M0  I  NS  0  0  2014ccRCC02  male  right  T1  N0  M0  I  MS  0  FS  2014ccRCC03  male  left  T1  N0  M0  I  0  0  0  2014ccRCC04  female  left  T1  N0  M0  I  0  0  0  2014ccRCC05  female  left  T2  N0  M0  II  0  0  0  2014ccRCC06  male  right  T1  N1  M0  III  NS  0  FS  2014ccRCC07  male  right  T1  N0  M0  I  FS  0  0  2014ccRCC08  male  right  T1  N0  M0  I  0  0  0  2014ccRCC09  male  right  T1  N0  M0  I  FS  0  0  2014ccRCC10  male  right  T2  N0  M0  II  0  0  0  2014ccRCC11  female  right  T3  N0  M0  III  MS  FS  FS  2014ccRCC12  male  right  T1  N0  M0  I  FS  0  0  2014ccRCC13  male  right  T3  N1  M0  III  FS  0  0  2014ccRCC14  male  left  T2  N1  M0  III  IFD  0  0  2014ccRCC15  male  left  T2  N1  M1  IV  0  MS  0  2014ccRCC16  female  left  T3  N0  M0  III  0  0  0  2014ccRCC17  male  left  T1  N0  M0  I  FS  0  0  2014ccRCC18  female  right  T1  N0  M0  I  MS  0  FS  2014ccRCC19  female  left  T2  N0  M0  II  0  0  0  2014ccRCC20  female  right  T1  N0  M0  I  MS  0  FS  2014ccRCC21  female  left  T1  N0  M0  I  NS  0  FS  2014ccRCC22  male  right  T2  N0  M0  II  FS  0  0  2014ccRCC23  female  right  T1  N0  M0  I  MS  0  FS  2014ccRCC24  male  left  T1  N0  M0  I  0  0  0  2014ccRCC25  female  right  T1  N0  M0  I  0  0  NS  2014ccRCC26  male  left  T1  N0  M0  I  FS  0  0  2014ccRCC27  male  left  T1  N1  M0  III  NS  0  0  2014ccRCC28  male  left  T1  N0  M0  I  FS  0  0  2014ccRCC29  female  left  T2  N0  M0  II  FS  0  0  2014ccRCC30  male  right  T1  N0  M0  I  0  0  0  2014ccRCC31  male  right  T1  N0  M0  I  NS  0  0  2014ccRCC32  male  left  T3  N0  M0  III  0  0  NS  2014ccRCC33  male  left  T4  N0  M0  IV  SS  MS  0  2014ccRCC34  male  right  T3  N0  M0  III  0  0  0  2014ccRCC35  female  right  T2  N0  M0  II  0  0  0  2014ccRCC36  male  left  T1  N0  M0  I  0  0  NS  2014ccRCC37  female  left  T2  N0  M0  II  0  0  0  2014ccRCC38  male  left  T1  N0  M0  I  0  0  MS  2014ccRCC39  male  left  T1  N0  M0  I  FS  0  0  2014ccRCC40  male  left  T2  N0  M0  II  MS  0  FS  2014ccRCC41  female  right  T1  N0  M0  I  FS  0  0  2014ccRCC42  male  right  T2  N0  M0  II  0  0  0  2014ccRCC43  male  right  T1  N0  M0  I  0  0  0  2014ccRCC44  female  left  T4  N0  M1  IV  0  0  0  2014ccRCC45  male  left  T1  N0  M0  I  0  0  0  2014ccRCC46  female  left  T3  N0  M0 III 0 0 0 *VHL, PBRM1, and BAP1 mutation was analysis by using PCR amplification and bidirectional Sanger sequencing. FS -frameshift. IFD -In-frame deletion. SS -Splice Site. NS -Nonsense. MS -Missense. 
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